ロード中...
Evaluating immune responses after sipuleucel-T therapy
Following FDA approval of sipuleucel-T in 2010 for metastatic castration resistant prostate cancer (mCRPC), several studies have described the effect of sipuleucel-T on peripheral immune responses. Retrospective associations have also been made with immune responses and survival. A recently publishe...
保存先:
| 出版年: | Cancer Biol Ther |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622939/ https://ncbi.nlm.nih.gov/pubmed/26054644 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2015.1056417 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|